The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) titled \Dr Reddys antibiotic gets Thailand approval six months after US nod\.
The Company is requested to submit its clarification to the Exchange in terms of the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015.